News

latest corporate presentation

Latest Summary Corporate Presentation

November 2023

View Presentation
10 Oct 2022 The Motley Fool Guess which ASX biotech share just rocketed 56% on new Alzheimer’s drug trial results
10 Oct 2022 Market Screener Actinogen Medical Validates Efficacy of Alzheimer’s Disease Therapy; Shares Surge 30%
10 Oct 2022 ShareCafe Stocks of the Hour: HLX, ACW, GAL
10 Oct 2022 Market Index Actinogen up 30% on strong Alzheimer’s trial results, says Xanamem product can slow progression
10 Oct 2022 Actinogen Company presentation: Alzheimer’s Disease biomarker study clinical results – Large clinical benefit on FDA-approved measurement of cognition and function in patients with Alzheimer’s Disease
10 Oct 2022 PR Newswire Actinogen Medical Limited (ACW) announces large Xanamem therapeutic effect in early-stage Alzheimer’s Disease (AD) patients
29 Sep 2022 Stocks Down Under Actinogen Medical (ASX: ACW): Good news on phase 2 trials can catapult this stock
13 Sep 2022 Actinogen Company presentation: Xanamem® Clinical Program Update – Alzheimer’s Disease (AD) biomarkers – context and history
11 Aug 2022 Actinogen Company presentation: CEO presentation for non-deal roadshow investor meetings
03 Aug 2022 Actinogen Webcast video recording: Actinogen Clinical Trials Science Forum
03 Aug 2022 Actinogen Company presentation: Actinogen Clinical Trials Science Forum
28 Jul 2022 Actinogen Company presentation: CEO presentation to Spark Plus Australian Equities Day
14 Jul 2022 Mirage News Actinogen confirms Alzheimer’s disease biomarker study timing and design
27 Jun 2022 FN Arena Australian Broker Call *Extra* Edition – Jun 27, 2022 | Bell Potter initiates coverage on Australian drug developer Actinogen Medical
14 Jun 2022 Actinogen Company presentation: CEO presentation for meetings at BIO International Convention
14 Jun 2022 The Market Herald Actinogen Medical (ASX:ACW) announces phase two trial designs for AD & MDD
14 Jun 2022 Biotech Daily Actinogen Medical Plans Xanamem For Alzheimer’s, Depression Phase II Trials
14 Jun 2022 The Sentiment Why one contentious FDA drug approval is good news for Actinogen Medical
14 Jun 2022 IQ Stock Actinogen Announces Phase 2 Trials in Alzheimer’s Disease and Depression
14 Jun 2022 Global Newswire Actinogen Announces Phase 2 Trials in Alzheimer’s Disease and Depression
14 Jun 2022 Yahoo Finance Actinogen Announces Phase 2 Trials in Alzheimer’s Disease and Depression
14 Jun 2022 Biospace Actinogen Announces Phase 2 Trials in Alzheimer’s Disease and Depression
11 May 2022 Actinogen Company presentation: Bioshares Biotech Summit 2022
04 May 2022 Actinogen Company presentation: ACW trial results & strategic update presentation
04 May 2022 The Market Herald Actinogen (ASX:ACW) prioritises Alzheimers disease and depression trials
04 May 2022 Market Index Actinogen reassesses its priorities: Clinical programs refocus on cognition
02 May 2022 Aged Care Insite Is Xanamem the Alzheimer’s breakthrough we’ve all been waiting for?
28 Apr 2022 Eminetra Australia Positive test results for Alzheimer’s drug Xanamem
28 Apr 2022 TechInvest Actinogen announces positive XanaMIA Part A trial
28 Apr 2022 Aged Care News Millions could benefit after breakthrough Alzheimer’s treatment trial by Aussie biotech
28 Apr 2022 Hospital and Healthcare Positive trial results for Alzheimer’s drug Xanamem
27 Apr 2022 Actinogen Webcast video recording: XanaMIA Part A Trial positive topline results for Xanamem
27 Apr 2022 Biotech Daily Actinogen XanaMIA Phase 1B Part A Trial Meets Endpoints
27 Apr 2022 The Sentiment New trial results from Actinogen hold promise for Alzheimer’s treatment
27 Apr 2022 The Market Herald Actinogen Medical (ASX:ACW) reports positive XanaMIA Part A trial topline results
27 Apr 2022 Kalkine Media Actinogen gets upbeat results from Xanamem trial for Alzheimer’s treatment
27 Apr 2022 Mirage News Millions worldwide could benefit after breakthrough trial in treatment for Alzheimer’s
27 Apr 2022 Actinogen Company presentation: XanaMIA Part A Trial positive topline results for Xanamem
27 Apr 2022 Australian Associated Press Millions worldwide could benefit after a breakthrough trial in the treatment for Alzheimer’s
27 Apr 2022 news.com.au Millions worldwide could benefit after a breakthrough trial in the treatment for Alzheimer’s
27 Apr 2022 The Australian Millions worldwide could benefit after a breakthrough trial in the treatment for Alzheimer’s
27 Apr 2022 The National Tribune Millions worldwide could benefit after breakthrough trial in treatment for Alzheimer’s
27 Apr 2022 Actinogen Media Release: Millions worldwide could benefit after a breakthrough trial in the treatment for Alzheimer’s by Aussie biotech Actinogen
26 Apr 2022 Clinical Trials Arena Pipeline Moves: Actinogen makes strides in mild cognitive impairment
01 Mar 2022 Actinogen Company presentation: CEO presents at Sachs 15th Annual European Life Sciences Conference
11 Feb 2022 The Market Herald Actinogen Medical (ASX:ACW) advances Alzheimer’s treatment
09 Feb 2022 The Sentiment Actinogen appoints leading researchers to conduct Phase 2 trials for treatment of Fragile X Syndrome
09 Feb 2022 The Market Herald Actinogen Medical (ASX:ACW) locks in trial manager for FXS phase-two study
09 Feb 2022 Biotech Daily Worldwide To Manage Xanamem Fragile X Trial
10 Jan 2022 Actinogen Company presentation: CEO presents at San Francisco Healthcare Conference
Load more

Back
to top